S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
146 Pounds of Graphite Needed for Each EV (Ad)
Is Frontline's 20% Dividend Too Good To Be True?
Stock market today: World stocks mixed as Wall St inches toward bull market
The $193 Billion US-China War You Don't Know About (Ad)
Wheat prices jump following collapse of major dam in southern Ukraine
Here’s What’s Driving the Price of Carvana Higher
The $193 Billion US-China War You Don't Know About (Ad)
Tesla: How and Why It Gets To $300
It Is Not Too Late To “Git” On Board With GitLab 
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
146 Pounds of Graphite Needed for Each EV (Ad)
Is Frontline's 20% Dividend Too Good To Be True?
Stock market today: World stocks mixed as Wall St inches toward bull market
The $193 Billion US-China War You Don't Know About (Ad)
Wheat prices jump following collapse of major dam in southern Ukraine
Here’s What’s Driving the Price of Carvana Higher
The $193 Billion US-China War You Don't Know About (Ad)
Tesla: How and Why It Gets To $300
It Is Not Too Late To “Git” On Board With GitLab 
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
146 Pounds of Graphite Needed for Each EV (Ad)
Is Frontline's 20% Dividend Too Good To Be True?
Stock market today: World stocks mixed as Wall St inches toward bull market
The $193 Billion US-China War You Don't Know About (Ad)
Wheat prices jump following collapse of major dam in southern Ukraine
Here’s What’s Driving the Price of Carvana Higher
The $193 Billion US-China War You Don't Know About (Ad)
Tesla: How and Why It Gets To $300
It Is Not Too Late To “Git” On Board With GitLab 
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
146 Pounds of Graphite Needed for Each EV (Ad)
Is Frontline's 20% Dividend Too Good To Be True?
Stock market today: World stocks mixed as Wall St inches toward bull market
The $193 Billion US-China War You Don't Know About (Ad)
Wheat prices jump following collapse of major dam in southern Ukraine
Here’s What’s Driving the Price of Carvana Higher
The $193 Billion US-China War You Don't Know About (Ad)
Tesla: How and Why It Gets To $300
It Is Not Too Late To “Git” On Board With GitLab 

Karuna Therapeutics (KRTX) Stock Forecast, Price & News

$236.30
+2.02 (+0.86%)
(As of 06/6/2023 ET)
Compare
Today's Range
$233.60
$238.48
50-Day Range
$176.32
$236.30
52-Week Range
$93.47
$278.25
Volume
432,971 shs
Average Volume
285,887 shs
Market Capitalization
$8.85 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$277.13

Karuna Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.87 Rating Score
Upside/​Downside
16.6% Upside
$275.44 Price Target
Short Interest
Bearish
5.56% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.31mentions of Karuna Therapeutics in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$13.03 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($11.67) to ($11.04) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.62 out of 5 stars

Medical Sector

829th out of 982 stocks

Pharmaceutical Preparations Industry

408th out of 476 stocks


KRTX stock logo

About Karuna Therapeutics (NASDAQ:KRTX) Stock

Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company was founded by Andrew Miller, Eric Elenko, and Peter Jeffrey Conn in July 2009 and is headquartered in Boston, MA.

Receive KRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Karuna Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KRTX Stock News Headlines

The $193 Billion US-China War You Don't Know About
They're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.
Citi Keeps Their Buy Rating on Karuna Therapeutics (KRTX)
Nevada Desert more Valuable than Wall Street or Silicon Valley?
It could be true, according to Nevada Governor Steve Sisolak. The state's desert flats contain more lithium than any other geography in the world. And with electric vehicles driving a global boom in demand for lithium-ion batteries, Nevada should be on every investor's radar.
Karuna Therapeutics (NASDAQ:KRTX) Stock Price Down 5.6%
Berenberg Bank Remains a Buy on Karuna Therapeutics (KRTX)
See More Headlines

KRTX Price History

KRTX Company Calendar

Last Earnings
5/04/2023
Today
6/06/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KRTX
Fax
N/A
Employees
118
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$275.44
High Stock Price Forecast
$330.00
Low Stock Price Forecast
$209.00
Forecasted Upside/Downside
+17.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.87
Research Coverage
15 Analysts

Profitability

Net Income
$-276,340,000.00
Net Margins
-2,795.96%
Pretax Margin
-2,783.40%

Debt

Sales & Book Value

Annual Sales
$10.64 million
Book Value
$32.78 per share

Miscellaneous

Free Float
31,378,000
Market Cap
$8.85 billion
Optionable
Not Optionable
Beta
1.15

Key Executives

  • William J. Meury
    President, Chief Executive Officer & Director
  • Andrew Miller
    Chief Operating Officer
  • Troy A. IgnelziTroy A. Ignelzi
    Chief Financial Officer
  • Stephen BrannanStephen Brannan
    Chief Medical Officer
  • Steven Marc PaulSteven Marc Paul
    Director, Chief Scientific Officer, President-R&D













KRTX Stock - Frequently Asked Questions

Should I buy or sell Karuna Therapeutics stock right now?

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Karuna Therapeutics in the last twelve months. There are currently 2 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KRTX shares.
View KRTX analyst ratings
or view top-rated stocks.

What is Karuna Therapeutics' stock price forecast for 2023?

15 Wall Street analysts have issued 1-year target prices for Karuna Therapeutics' stock. Their KRTX share price forecasts range from $209.00 to $330.00. On average, they predict the company's stock price to reach $275.44 in the next year. This suggests a possible upside of 16.6% from the stock's current price.
View analysts price targets for KRTX
or view top-rated stocks among Wall Street analysts.

How have KRTX shares performed in 2023?

Karuna Therapeutics' stock was trading at $196.50 on January 1st, 2023. Since then, KRTX stock has increased by 20.3% and is now trading at $236.30.
View the best growth stocks for 2023 here
.

When is Karuna Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our KRTX earnings forecast
.

How were Karuna Therapeutics' earnings last quarter?

Karuna Therapeutics, Inc. (NASDAQ:KRTX) posted its earnings results on Thursday, May, 4th. The company reported ($2.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.86) by $0.06. The business earned $0.65 million during the quarter. Karuna Therapeutics had a negative trailing twelve-month return on equity of 30.04% and a negative net margin of 2,795.96%. During the same period in the previous year, the company posted ($1.95) earnings per share.

What other stocks do shareholders of Karuna Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Karuna Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), AbbVie (ABBV), Pfizer (PFE), Alibaba Group (BABA), Johnson & Johnson (JNJ), AT&T (T), Target (TGT) and Walt Disney (DIS).

When did Karuna Therapeutics IPO?

(KRTX) raised $70 million in an initial public offering on Friday, June 28th 2019. The company issued 4,400,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Citigroup and Wells Fargo Securities acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Karuna Therapeutics' stock symbol?

Karuna Therapeutics trades on the NASDAQ under the ticker symbol "KRTX."

Who are Karuna Therapeutics' major shareholders?

Karuna Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (14.97%), Price T Rowe Associates Inc. MD (6.63%), BlackRock Inc. (6.60%), Wellington Management Group LLP (4.29%), State Street Corp (2.66%) and Geode Capital Management LLC (1.61%). Insiders that own company stock include Andrew Craig Miller, Atul Pande, Edmund Harrigan, Heather Preston, James Healy, Laurie J Olson, Laurie J Olson, Puretech Health Llc, Stephen K Brannan, Steven M Paul and Troy A Ignelzi.
View institutional ownership trends
.

How do I buy shares of Karuna Therapeutics?

Shares of KRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Karuna Therapeutics' stock price today?

One share of KRTX stock can currently be purchased for approximately $236.30.

How much money does Karuna Therapeutics make?

Karuna Therapeutics (NASDAQ:KRTX) has a market capitalization of $8.85 billion and generates $10.64 million in revenue each year. The company earns $-276,340,000.00 in net income (profit) each year or ($9.57) on an earnings per share basis.

How many employees does Karuna Therapeutics have?

The company employs 118 workers across the globe.

How can I contact Karuna Therapeutics?

Karuna Therapeutics' mailing address is 33 ARCH STREET SUITE 3110, BOSTON MA, 02110. The official website for the company is karunatx.com. The company can be reached via phone at (857) 449-2244 or via email at investors@karunatx.com.

This page (NASDAQ:KRTX) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -